Business, energy, technology, markets and global industry news from Business News Today
Pharma & Biotech

CagriSema delivered 25% weight loss in early responders. What does that reveal about Novo Nordisk’s obesity drug?

Novo Nordisk A/S (NYSE: NVO) announced on November 15, 2026, that a new post hoc analysis of its Phase 3 REDEFINE 1 trial found mean weight loss of 25.4% at Week 68 among CagriSema-treated participants who had already lost at least 5% of their body weight by Week 8. The analysis, presented at ObesityWeek 2026, also found that participants who responded more slowly achieved mean weight loss of 17.8% over the same period, highlighting substantial variation in individual weight loss trajectories with the investigational once-weekly treatment.

The findings provide additional information about treatment response patterns as Novo Nordisk approaches an anticipated United States Food and Drug Administration decision on CagriSema’s weight management application. Approximately 67.8% of treated participants included in the exploratory analysis met the definition of an early responder. A separate post hoc analysis also reported meaningful improvements in patient-reported physical and psychosocial functioning compared with placebo.

The most important distinction is that the 25.4% figure represents an observed result within a selected subgroup, not the average treatment effect across everyone assigned to CagriSema in REDEFINE 1. The original randomised Phase 3 study reported average weight loss of 20.4% under its treatment-policy analysis and an estimated 22.7% under an efficacy estimand assuming treatment adherence. The new findings are hypothesis-generating and do not establish that early response can reliably determine how an individual patient should be treated.

What does the new REDEFINE 1 analysis reveal about CagriSema weight loss?

REDEFINE 1 was a 68-week, double-blind, placebo- and active-controlled Phase 3 trial involving 3,417 adults with obesity or overweight and at least one related health condition, without type 2 diabetes. Participants were assigned to CagriSema, semaglutide alone, cagrilintide alone or placebo alongside lifestyle interventions. The trial established the efficacy of combining the two hormonal mechanisms for weight management under the studied conditions.

The new analysis examined whether weight loss during the first eight weeks was associated with outcomes at the end of treatment. Researchers defined early responders as participants who had lost at least 5% of their baseline body weight by Week 8. Those who had not reached that threshold were classified as delayed responders.

Among the CagriSema participants included in the analysis, 1,367 met the early-response definition and 649 were classified as delayed responders. At Week 8, the early group had lost an average of 7.8% of baseline body weight, compared with 3.4% among delayed responders. By Week 68, the corresponding observed mean weight reductions were 25.4% and 17.8%.

The difference suggests that early weight loss was associated with the magnitude of subsequent weight reduction within the analysed population. However, the relationship should not be treated as evidence that early response itself caused the larger final result. Participants were grouped according to a treatment outcome that had already occurred rather than randomly assigned to different early-response categories.

The mathematical relationship between early and later weight loss also matters. A participant who loses more weight during the first eight weeks already has a greater cumulative reduction at that point. Further analysis is required to establish whether the early result independently predicts subsequent changes after accounting for baseline characteristics and treatment exposure.

The findings nevertheless provide useful information about the range of treatment trajectories observed in REDEFINE 1. They suggest that a substantial proportion of participants experienced relatively rapid weight reduction, while others required more time to achieve larger cumulative changes.

Why did delayed responders still achieve substantial weight loss?

One of the most clinically relevant findings is that delayed responders continued losing weight after the initial eight-week period. Their observed mean weight reduction reached 17.8% by Week 68, despite failing to achieve the 5% threshold at the earlier assessment. This suggests that an initially slower response did not necessarily indicate an absence of meaningful treatment benefit.

The subgroup results also showed that 37.2% of delayed responders achieved weight loss of at least 20% by Week 68. By comparison, 73.3% of early responders reached that threshold. The difference is substantial, but the delayed group’s result demonstrates that a slower start was compatible with considerable later weight reduction.

These findings are relevant because patients and clinicians may seek early indicators of whether a medicine is working. In clinical practice, however, treatment decisions depend on several factors, including tolerability, adherence, dose escalation and overall health. A threshold identified through retrospective analysis should not automatically become a rule for continuing or discontinuing treatment.

CagriSema’s treatment schedule also involves dose escalation, meaning the first eight weeks do not necessarily represent the same treatment exposure as later phases of the trial. Differences in individual tolerability and dose progression may influence early results. The November analysis does not establish how much each of these factors contributed to the observed trajectories.

An initially modest weight reduction may therefore warrant continued clinical assessment rather than an immediate conclusion that treatment has failed. At the same time, the exploratory findings cannot establish the optimal treatment duration for every patient. Such decisions require appropriate prescribing guidance and prospective evidence.

Novo Nordisk’s researchers have characterised the analyses as hypothesis-generating rather than a basis for changing clinical decision-making. That qualification is essential because the study was not designed to test an early-response treatment algorithm.

How should the 25.4% result be compared with the original Phase 3 outcome?

The original REDEFINE 1 results demonstrated that CagriSema produced greater weight loss than placebo and either component administered alone. Under the treatment-policy estimand, which reflects outcomes regardless of treatment discontinuation or certain subsequent treatment changes, estimated average weight loss was 20.4% with CagriSema compared with 3.0% for placebo.

The corresponding estimates were 14.9% for semaglutide alone and 11.5% for cagrilintide alone. These findings established a benefit for the combination within the controlled trial. The estimated treatment difference between CagriSema and placebo was 17.3 percentage points under the primary analysis framework.

Under the efficacy estimand, which considers a hypothetical scenario in which participants adhered to the assigned treatment, Novo Nordisk reported an estimated average weight reduction of 22.7% with CagriSema. That figure answers a different statistical question from the treatment-policy result and should not be presented as directly interchangeable.

The newly reported 25.4% is different again. It comes from observed on-treatment data among participants meeting a specific Week 8 response threshold. It is neither the overall trial result nor a separately randomised comparison demonstrating that one patient category benefits more than another.

These distinctions are particularly important in obesity treatment reporting because different percentages can appear to describe the same outcome while reflecting different assumptions. A treatment-policy estimate, an efficacy estimand and an observed subgroup average each answer a different question. Combining them without qualification can produce misleading conclusions about expected individual outcomes.

The most robust evidence of CagriSema’s weight reduction remains the original randomised Phase 3 analysis. The new findings are useful for understanding variation within the treated population but do not replace the primary trial result or establish a new efficacy claim.

What do the latest results show about achieving major weight loss thresholds?

The early-response analysis examined the proportion of participants achieving different weight loss thresholds at Week 68. Among early responders, 73.3% achieved weight loss of at least 20%. Another 16.1% lost between 15% and less than 20%, while 7.9% lost between 10% and less than 15%.

Among delayed responders, 37.2% achieved weight loss of at least 20%, while 23.8% lost between 15% and less than 20%. Another 21.3% achieved a reduction between 10% and less than 15%. Only 3.6% of delayed responders recorded less than 5% weight loss by Week 68 in the observed dataset.

These results demonstrate that the difference between early and delayed groups was largely one of response magnitude rather than a simple division between treatment success and failure. Many participants who did not lose 5% by Week 8 nevertheless achieved substantial reductions during the remainder of the trial. This may be useful when discussing the time course of weight loss, although the results remain exploratory.

The categories also highlight the importance of distinguishing mean outcomes from individual responses. An average reduction of 25.4% does not mean that every early responder lost approximately one-quarter of their body weight. The actual distribution included participants achieving different levels of weight reduction.

The analysis does not establish whether early responders experienced equivalent improvements in cardiometabolic risk factors or long-term health outcomes. Weight loss magnitude may be relevant to several clinical conditions, but additional evidence is required to determine how the observed trajectories relate to specific complications or sustained health benefits.

The subgroup findings therefore deepen understanding of CagriSema’s observed response patterns without establishing a personalised treatment strategy. Further work would be needed before a clinician could reliably use early weight loss alone to predict an individual’s eventual outcome.

What does the female responder analysis reveal about treatment variation?

Novo Nordisk also reported differences in the sex distribution of the early- and delayed-response groups. Women accounted for 71.8% of early responders and 59.5% of delayed responders. This indicates that women represented a larger share of the early-response group than of the delayed-response group.

The distinction between group composition and individual response probability is important. The reported percentages do not directly mean that 71.8% of all women receiving CagriSema became early responders. They describe the proportion of women within the two response categories.

Differences in baseline weight, body composition, hormonal status and other patient characteristics could influence observed response patterns. However, the current analysis does not establish why the groups differed or identify a biological mechanism explaining the result. It should therefore not be interpreted as proof that sex independently determines early treatment response.

Novo Nordisk has separately investigated CagriSema results by sex and menopausal status in other exploratory analyses. Those studies may provide additional context, but results from different subgroup investigations should not be merged into a single confirmatory conclusion. Each analysis has its own population, definitions and statistical limitations.

The commercial and clinical value of identifying potential response predictors would be substantial if they could be validated. Reliable predictors might eventually help clinicians understand which patients are more likely to benefit from a particular treatment. However, the November findings are not sufficient to establish such a tool.

For now, the sex distribution results should be understood as descriptive evidence about the analysed participants. They generate questions for further research rather than providing a basis for treatment selection.

Did CagriSema improve physical and psychosocial functioning?

A separate post hoc analysis from REDEFINE 1 examined patient-reported outcomes using the Impact of Weight on Quality of Life-Lite Clinical Trials Version questionnaire. The instrument evaluates how weight affects aspects of daily functioning and psychosocial wellbeing. Researchers assessed the proportion of participants reporting improvements that met predefined thresholds considered meaningful within the questionnaire framework.

At Week 68, 73.1% of participants receiving CagriSema achieved a meaningful improvement in the physical function score, compared with 49.1% receiving placebo. The estimated treatment difference was 24.1 percentage points, with a 95% confidence interval from 19.5 to 28.7 percentage points. These findings suggest that the treatment’s effects may extend beyond changes in body weight alone.

The psychosocial function analysis also favoured CagriSema. Approximately 69.0% of treated participants reported a meaningful improvement, compared with 42.1% receiving placebo. The estimated difference was 26.9 percentage points, providing supportive evidence concerning patient-reported wellbeing.

However, these analyses were post hoc and used an efficacy estimand assuming treatment adherence. The findings should not be presented as though every participant assigned to treatment experienced equivalent improvements under routine real-world conditions. Patient-reported outcomes also require interpretation alongside the questionnaire’s design and the characteristics of the study population.

Improvements in perceived physical function do not automatically establish gains in objectively measured fitness, muscle strength or cardiovascular performance. Similarly, changes in psychosocial scores provide valuable patient perspectives but do not prove that a medicine treats a separate psychiatric condition. The endpoints are relevant to quality of life within the context of obesity treatment.

The results nevertheless address an important aspect of treatment value. Patients may evaluate a weight management medicine partly through its effects on mobility, daily activities and perceived wellbeing. More detailed evidence about these outcomes could help clinicians and healthcare systems assess benefits that conventional weight measurements do not fully capture.

How do the new findings relate to CagriSema’s mechanism and wider development programme?

CagriSema combines cagrilintide, a long-acting amylin analogue, with semaglutide, a glucagon-like peptide-1 receptor agonist. Both components influence pathways associated with appetite and energy intake, although they act through different hormonal mechanisms. Novo Nordisk is investigating whether combining those effects can provide greater weight reduction than either component alone.

The treatment is administered through once-weekly subcutaneous injection in the clinical programme. Its fixed-dose combination creates a coordinated approach to activating two complementary pathways. However, the presence of two mechanisms does not independently establish superior long-term outcomes compared with every alternative obesity therapy.

Novo Nordisk has continued evaluating CagriSema across different doses and patient populations. At ObesityWeek 2026, the company also presented Phase 3 REDEFINE 9 results examining lower doses of the combination. Under the efficacy estimand, the 1.7 mg/1.7 mg and 1.0 mg/1.0 mg regimens produced estimated average weight reductions of 20.7% and 21.0%, respectively, after 68 weeks.

The lower-dose trial included substantially smaller treatment groups and was not powered to establish differences between the two CagriSema doses. Its results provide additional information about dose-related efficacy but do not demonstrate that the lower dose is clinically superior. The appropriate dose for any future approved product will depend on regulatory evaluation and the complete development evidence.

The broader programme also includes studies in adults with type 2 diabetes and additional obesity investigations. These trials address different populations and clinical objectives, making direct comparisons between isolated percentages potentially misleading. The new early-response analysis adds information about one specific aspect of the REDEFINE 1 population rather than determining outcomes across the entire programme.

What safety limitations remain relevant to CagriSema’s clinical profile?

The original REDEFINE 1 trial reported gastrointestinal adverse events in 79.6% of CagriSema-treated participants, compared with 39.9% receiving placebo. Nausea occurred in approximately 55% of the combination group, while constipation and vomiting were also commonly reported. Most gastrointestinal events were described as mild or moderate and transient.

However, adverse events were not universally mild, and tolerability contributed to treatment discontinuation. Approximately 5.9% of CagriSema-treated participants discontinued because of adverse events, compared with 3.5% in the placebo group. These figures provide important context when evaluating the treatment’s average weight loss.

The latest responder analysis does not establish whether patients with greater early weight loss experienced different adverse-event profiles from delayed responders. It also does not determine whether gastrointestinal symptoms influenced adherence or dose escalation in ways that contributed to the observed weight loss trajectories. Such relationships would require appropriately designed analyses.

The safety profile is commercially important because obesity treatment often involves long-term medication use. A medicine may produce substantial weight reduction but still face adoption constraints if tolerability affects persistence. The balance between efficacy, adverse effects and the practical treatment regimen will influence how clinicians and patients evaluate the therapy.

CagriSema remains investigational and is not currently approved for use in the United States. The FDA must assess the complete efficacy, safety and manufacturing evidence before determining whether the proposed treatment can be marketed. The new post hoc findings are supportive research and do not substitute for that review.

Why does the upcoming FDA decision matter more than the 25% subgroup headline?

Novo Nordisk submitted a New Drug Application for CagriSema 2.4 mg/2.4 mg for weight management in December 2025. The company expects a regulatory decision during the fourth quarter of 2026, although the outcome remains uncertain. If approved, CagriSema could become an additional treatment option within a rapidly evolving obesity medicine market.

The primary regulatory evidence rests on the complete Phase 3 programme rather than the recently disclosed early-responder analysis. Regulators will evaluate the treatment’s overall efficacy, tolerability, manufacturing quality and proposed labelling. Exploratory findings may provide useful context but cannot independently establish an indication or determine the appropriate treatment population.

Commercial differentiation will also be demanding. Existing incretin-based medicines have established substantial weight loss efficacy, while competitors are developing additional hormonal combinations and oral therapies. A newly approved product must demonstrate a sufficiently attractive overall treatment profile rather than relying on one favourable subgroup percentage.

Novo Nordisk’s United States-listed shares closed at $41.63 on November 13, 2026, up 2.41% during that trading session. The closing price preceded the November 15 release, meaning it cannot be interpreted as a market response to the new analysis. Investor sentiment will continue to reflect expectations surrounding the FDA decision, product competition and the company’s wider diabetes and obesity portfolio.

The clinical findings may support confidence in CagriSema’s ability to produce substantial weight reduction across different response trajectories. However, they do not remove uncertainty concerning approval or establish that the medicine will achieve the commercial position anticipated by management. Pricing, reimbursement, manufacturing capacity and patient persistence will influence its eventual market performance.

What will determine whether early CagriSema response becomes clinically useful?

The November 15 analysis identifies an association between weight reduction during the first eight weeks and observed outcomes after 68 weeks. It also demonstrates that delayed responders can achieve substantial later weight loss, providing a useful counterpoint to the assumption that slow initial progress necessarily predicts limited eventual benefit. These findings are scientifically relevant but remain exploratory.

Before early response can be used to guide treatment decisions, researchers would need to establish whether the association is reproducible and clinically predictive in independent populations. Analyses should account for baseline characteristics, dose exposure, adherence and the mathematical contribution of early weight loss to the final outcome. Prospective evaluation would provide stronger evidence than retrospective subgroup comparisons alone.

The patient-reported function results add another dimension by suggesting benefits beyond body weight measurements. However, they also require careful interpretation because they were generated through post hoc analyses and a defined statistical estimand. Their significance will become clearer as the broader clinical evidence develops.

Novo Nordisk’s immediate milestone remains the FDA’s decision on CagriSema’s application. The latest REDEFINE 1 findings deepen understanding of how patients responded during the trial, but the original randomised efficacy and safety results remain the foundation of the regulatory case.

CagriSema’s 25.4% mean weight reduction among early responders is a notable observation, not a universal prediction of treatment outcomes. The more informative conclusion is that both early and delayed responders experienced substantial average weight loss within the analysed population. Whether this knowledge eventually improves individualised obesity treatment will depend on prospective validation and the clinical experience generated if CagriSema receives regulatory approval.

Leave a Reply

Your email address will not be published. Required fields are marked *